MedTrace Logo

CART22 Alone or in Combination With huCART19 for ALL

NCT03620058 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-10-14

No results posted yet for this study

Summary

This is a single center, open-label, phase 1 study to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.

Conditions

  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

CART22-65s cells

Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB

BIOLOGICAL

huCART19 Cells

Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB

Sponsors & Collaborators

Principal Investigators

  • Noelle Frey, MD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-27
Primary Completion
2036-01-31
Completion
2036-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620058 on ClinicalTrials.gov